Payment overview · 2025
General Payments
$108.49
5 reported records · 4 companies
Healthcare provider profile · identity verified
Christopher Barclay Hamm, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DES PERES, MO · NPI 1730490830
Verified facts
What the public records show
CMS Open Payments records show Christopher Barclay Hamm, M.D. received $108.49 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 40.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.07 | 40.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.91 | 21.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.68 | 20.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.83 | 17.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $108.49 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.07 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.07 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 47 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
47 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1707 | 497 |
| Amlodipine Besylate | Amlodipine Besylate | 659 | 191 |
| Levothyroxine Sodium | Levothyroxine Sodium | 587 | 159 |
| Pantoprazole Sodium | Pantoprazole Sodium | 502 | 164 |
| Losartan Potassium | Losartan Potassium | 424 | 129 |
| Alprazolam | Alprazolam | 419 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 404 | 121 |
| Lisinopril | Lisinopril | 393 | 117 |
| Omeprazole | Omeprazole | 369 | 117 |
| Tramadol Hcl | Tramadol Hcl | 361 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 350 | 103 |
| Eliquis | Apixaban | 345 | 86 |
| Montelukast Sodium | Montelukast Sodium | 261 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 259 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 240 | 95 |
| Trazodone Hcl | Trazodone Hcl | 236 | 82 |
| Fluticasone Propionate | Fluticasone Propionate | 226 | 102 |
| Zolpidem Tartrate | Zolpidem Tartrate | 207 | 48 |
| Furosemide | Furosemide | 198 | 76 |
| Finasteride | Finasteride | 190 | 58 |
| Meloxicam | Meloxicam | 182 | 62 |
| Metformin Hcl Er | Metformin Hcl | 179 | 61 |
| Simvastatin | Simvastatin | 179 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 169 | 51 |
| Gabapentin | Gabapentin | 168 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 159 | 46 |
| Metformin Hcl | Metformin Hcl | 153 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 48 |
| Sertraline Hcl | Sertraline Hcl | 152 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 59 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 142 | 42 |
| Prednisone | Prednisone | 141 | 94 |
| Carvedilol | Carvedilol | 130 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 49 |
| Mirtazapine | Mirtazapine | 124 | 38 |
| Bupropion Xl | Bupropion Hcl | 121 | 42 |
| Atenolol | Atenolol | 117 | 33 |
| Allopurinol | Allopurinol | 111 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 31 |
| Pregabalin | Pregabalin | 106 | 28 |
| Lorazepam | Lorazepam | 103 | 25 |
| Alendronate Sodium | Alendronate Sodium | 102 | 32 |
| Famotidine | Famotidine | 101 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 30 |
| Temazepam | Temazepam | 96 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 95 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 28 |
| Donepezil Hcl | Donepezil Hcl | 88 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 85 | 22 |
| Ezetimibe | Ezetimibe | 84 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 83 | 19 |
| Januvia | Sitagliptin Phosphate | 80 | 20 |
| Potassium Chloride | Potassium Chloride | 79 | 29 |
| Sumatriptan Succinate | Sumatriptan Succinate | 78 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 77 | 24 |
| Cefuroxime | Cefuroxime Axetil | 77 | 67 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 18 |
| Oxycontin | Oxycodone Hcl | 77 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 23 |
| Clonazepam | Clonazepam | 76 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 21 |
| Spironolactone | Spironolactone | 76 | 31 |
| Jardiance | Empagliflozin | 75 | 21 |
| Colestipol Hcl | Colestipol Hcl | 65 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 65 | 20 |
| Azelastine Hcl | Azelastine Hcl | 64 | 26 |
| Morphine Sulfate Er | Morphine Sulfate | 63 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 62 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 22 |
| Diazepam | Diazepam | 59 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 18 |
| Valacyclovir | Valacyclovir Hcl | 55 | 23 |
| Synthroid | Levothyroxine Sodium | 53 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 52 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 17 |
| Ozempic | Semaglutide | 48 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 47 | 47 |
| Glimepiride | Glimepiride | 47 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 15 |
| Ramipril | Ramipril | 44 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | 20 |
| Celecoxib | Celecoxib | 42 | 16 |
| Xarelto | Rivaroxaban | 42 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | suppressed |
| Acyclovir | Acyclovir | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 12 |
| Farxiga | Dapagliflozin Propanediol | 34 | 11 |
| Glipizide Er | Glipizide | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | 16 |
| Baclofen | Baclofen | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 11 |
| Ketoconazole | Ketoconazole | 30 | 19 |
| Olanzapine | Olanzapine | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 16 |
| Klor-Con M20 | Potassium Chloride | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | 11 |
| Fluconazole | Fluconazole | 28 | 11 |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 22 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | 12 |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | 11 |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 15 |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Nystatin | Nystatin | 19 | 11 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Colchicine | Colchicine | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Pilocarpine Hcl | Pilocarpine Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Norelgestromin-Eth Estradiol | Norelgestromin/Ethin.Estradiol | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $108.49 · 5 records | ABBVIE INC. | AREXVY, FREESTYLE LIBRE 3, MOUNJARO, QULIPTA, SHINGRIX, UBRELVY, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error